SciBase Announces Additional Order From Castle Biosciences Valued At About $0.6M For Nevisense Go Devices And Electrodes To Accelerate Ongoing Atopic Dermatitis Study, Prepare Second Study; Deliveries Expected To Begin Q4 2026
Share
Why It Matters
Castle Biosciences ordered more skin-scanning devices from SciBase to test a medicine for itchy skin problems. This shows Castle believes the technology works and wants to expand their research.
This read is generated by AI from raw market data and is for education only. It is not financial advice, not a signal, and not a recommendation to buy or sell.
Tickers in Play
Last session drawn · prints held ~15 minutes · licensed exchange data
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only — not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.